All News

Article

Belimumab in Lupus Nephritis

Jack Cush, MD May 29, 2023

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Article

3-4-5 Rule (5.26.2023)

Jack Cush, MD May 26, 2023

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Article

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

EurekAlert! May 25, 2023

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

Article

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Article

Juvenile and Adult-onset Scleroderma Differ

Jack Cush, MD May 15, 2023

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.

Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00457-9

#EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed: - Tapering was NOT associated with subsequent flare - Tapering reduced damage in those on =>5mg/day @RheumNow https://t.co/Q6GiaSCgV6

Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy

Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY Congratulations @LupusEurope! #EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro

Lupus 100 – lupus100

Different B cell depleting agents! #Eular2023 https://t.co/GsmdIHgOcl

#Precision medicine in #SLE #Interferon is not a good predictor of remission as it takes a LONG time to normalize in #Lupus @RheumNow @eular_org #EULAR2023 abst#OP https://t.co/JkWnk94bHu

#EULAR2023 Please find my first article on Congress Preview of Promising New Therapies in #lupus #SLE @RheumNow https://t.co/SFvhsP8QWO https://t.co/m5UwBGCXFB

Promising new therapies in SLE: preview of EULAR23 | RheumNow

Lupus Landmark Study to Accelerate Personalized Lupus Treatments The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE. https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH

https://bit.ly/3WD66Z7

Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk

SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w

https://bit.ly/45rVqAs

ICYMI: Our old friend, hydroxychloroquine https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3

https://bit.ly/3MzRdU1

Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9

https://bit.ly/3MrcZt6

Review of the etiology of Polyserositis (14 pts, 23 articles): most common - neoplasia (26.3%; Lung Lymphoma; ovarian; pancreatic), autoimmune (16.7% - SLE, AOSD) & infections (12.3%; coxackie, CMV, mTB). https://t.co/Bubd99ETgu https://t.co/VbiPB0y7pv

https://bit.ly/3IbBuIa

Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included: - SLE onset age ≤ 30 (HR 1.6) - Arthritis (HR 1.6) - Organ damage (HR 2.6) - RNP+ (HR 1.7) - High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x

https://bit.ly/41A7hJD

Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx

https://bit.ly/3M7mb4w

Topics

All News

Belimumab in Lupus Nephritis

3-4-5 Rule (5.26.2023)

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

Allergic Drug-Induced Arthritis (5.19.2023)

Juvenile and Adult-onset Scleroderma Differ

Do you get our email newsletter?